In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2016 Pharma Dealmaking: Waiting On The High-Value Deals

Executive Summary

Six pharma deals announced thus far in 2016 carried up-front values of $1 billion or more, down considerably from the high-volume, high-value M&A industry experienced the prior two years. Pharma manufacturers appear to be recalibrating – digesting previous acquisitions, adjusting to new biotech valuations and taking stock of the political and macro-economic climate – but fundamentals suggest pharma dealmaking will pick up. Pfizer’s $14 billion offer for Medivation might represent a turning point.

Advertisement

Related Content

AstraZeneca Sells Small-Molecule Antibiotics To Pfizer But Still Investing In R&D
Teva Embarks On New Phase With FTC Clearance Of Allergan Generics
Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations
Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole
It's The End Of Pfizergan, So Pfizer Will Have To Grow It Alone
Valeant’s Pearson Is Out, As Hunt Begins For A CEO To Right The Wrongs
Meet The New $200bn Normal In M&A, EY Says
In Buzz Of 2015 Pharma Dealmaking, Immuno-Oncology Is Queen Bee
A Banner Year For Pharma: M&A Tops 2009 Merger Mania
Lilly and AstraZeneca gang up on Merck in Alzheimer's

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV004922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel